> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-212/
- Published: 2019-02-24T12:00:00.000Z
- Updated: 2026-09-15T01:07:18.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143460

[**Draft Guide on Nicotine Replacement Drug Products**](https://www.fdaweb.com/draft-guide-on-nicotine-replacement-drug-products/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products.” 02/22/2019

[**Rule on Bulk Drug Substances for Compounding**](https://www.fdaweb.com/rule-on-bulk-drug-substances-for-compounding/)  
*Federal Register* notice: FDA issues a final rule to establish criteria for and identify an initial list of bulk drug substances that can be used to compound drug products in accordance with certain compounding provisions of the Food, Drug, and Cosmetic Act. 02/20/2019

[**Class 2 for Titration Devices for Oral Appliances**](https://www.fdaweb.com/class-2-for-titration-devices-for-oral-appliances/)  
*Federal Register* notice: FDA classifies auto titration devices for oral appliances into Class 2 (special controls). 02/20/2019

[**Nonbinding Feedback After Device Inspections Guide**](https://www.fdaweb.com/nonbinding-feedback-after-device-inspections-guide/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Nonbinding Feedback After Certain FDA Inspections of Device Establishments.” 02/19/2019

[**Guide on Expedited Programs for Regenerative Medicine Therapies**](https://www.fdaweb.com/guide-on-expedited-programs-for-regenerative-medicine-therapies/)  
*Federal Register* notice: FDA posts a final guidance entitled “Expedited Programs for Regenerative Medicine Therapies for Serious Conditions.” 02/19/2019

[**Guide on Devices Used with Regenerative Medicine Therapies**](https://www.fdaweb.com/guide-on-devices-used-with-regenerative-medicine-therapies/)  
*Federal Register* notice: FDA makes available a final guidance entitled “Evaluation of Devices Used with Regenerative Medicine Advanced Therapies” that provides the agency’s current thinking about how it intends to simplify and streamline its application of regulatory requirements for combination device and cell or tissue products. 02/19/2019

[**Comments Reopened on Real World Evidence Program**](https://www.fdaweb.com/comments-reopened-on-real-world-evidence-program/)  
*Federal Register* notice: FDA reopens the comment period on a 12/7/2018 notice entitled “Framework for a Real-World Evidence Program; Availability.” 02/15/2019